The new facility will double Cytiva’s manufacturing capacity in India and provide critical training programmes to accelerate the development of novel therapeutics.
Enhance Your Healthcare Expertise with High-Impact Courses
|IIM Kozhikode||IIMK Healthcare Management & Analytics Programme||Visit|
The newly unveiled manufacturing facility in Pune will produce bioprocessing equipment, including tangential flow, virus filtration, and inactivation systems.
The Experience Centre will offer immersive training programmes covering upstream and downstream technologies, digital solutions, and automation software.
Located at Hinjawadi Rajiv Gandhi Infotech Park, the new facility complements Cytiva’s existing facilities in Bengaluru which include a Fast Trak Center, and a center for research and development across bioprocess, discovery, medical, and genomic medicine businesses.
“Fortifying our manufacturing footprint in India is critical to Cytiva’s operations in Asia-Pacific and long-term growth strategy,” said Rajan Sankaran, commercial general manager, India, Cytiva.”We must also play a key role in developing and nurturing the talent needed to meet the demand for biologic medicines,” Sankaran added.Cytiva’s 2023 Global Biopharma Resilience Index indicates that 65% of biopharma executives in India expect a significant rise in biologics manufacturing over the next three years. This figure is 15% above the global average. Moreover, 46% of Indian biopharma executives are prioritising onshoring drug manufacturing or increasing domestic sourcing in the upcoming 12 months to bolster supply chain resilience.
Cytiva was formerly called GE Healthcare Life Sciences.